Patent · US Active

Live genetically attenuated malaria vaccine

US7261884B2 · kind B2 · utility

1Cited by

2References

1Claims

0Family size

Assignees

Seattle Biomedical Research Institute · US
RUPRECHT - KARLS - UNIVERSITÄT HEIDELBERG · DE

Inventors

Stefan H. I. Kappe · Seattle, US
Kai-Uwe C. Matuschewski · Berlin, DE
Ann-Kristin Mueller · Dossenheim, DE

Key dates

Filing date	Aug 30, 2006
Grant date	Aug 28, 2007
Priority date	—
Expiry date	Aug 30, 2026

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a liver-stage-specific gene function.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.